Quality of medicines in Sri Lanka: a retrospective review of safety alerts

BMC Health Services Research

Research Article

Kaumada Binoli Herath¹  Jegath Janani Tharmalinga Sharma²  Madumai Ketharam³  Senathiraja Sherley Shobia³ 

[1] Institute for Research and Development in Health & Social Care, Colombo, Sri Lanka;Ministry of Health, Nutrition & Indigenous Medicine, Colombo South Teaching Hospital, Baddegama Wimalawansa Thero Mawatha, Colombo, Sri Lanka;National Medicines Regulatory Authority, Colombo, Sri Lanka;

关键词: Quality;    Medicines;    Withhold;    Recall;    Safety alerts;    Sri Lanka;   

DOI  :  10.1186/s12913-023-09995-3

 received in 2022-08-08, accepted in 2023-08-31,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundMany medicine quality problems are detected after they arrive at health facilities. Thus, critically defective medicines that may pose health risks to patients need to be withheld or recalled.AimsTo investigate the withheld and recalled medicines in relation to the types of defects, their total numbers, therapeutic categories, pharmaceutical dosage forms, and country of manufacturer during the study period.MethodsA retrospective review was performed on withheld and recalled medicines published on the publicly available National Medicines Regulatory Authority (NMRA) official website in Sri Lanka between June 2018 and August 2021. Details on substandard medicines (SM) were extracted and documented. Each record of SM was individually reviewed to determine the type of defect, subsequent action taken by NMRA, therapeutic category, pharmaceutical dosage form, and country of manufacturer.ResultsA total of 163 defects were identified in 143 defective medicines, among which the most common types of defects were contamination (n = 59, 36.2%), stability defects (n = 41, 25.2%), packaging and labelling defects (n = 27, 16.6%) and active pharmaceutical ingredient defects (n = 26, 15.9%). Out of 143 total defective medicines identified, anti-infectives accounted for 41.9%, while parenteral preparations (44.0%) were found to be frequently defective. Nearly 70% of the recalled and withheld medicines were of Indian origin, and some manufacturers were identified to be repeatedly involved.ConclusionsThis study revealed that contamination was the most frequent cause of defective medicines, while parenteral preparations and anti-infectives were the most susceptible pharmaceutical dosage form and therapeutic category found to be substandard, respectively. In addition, the findings show that some manufacturers were accountable for repetitive withholdings and recalls, which reflects the ignorance of quality control measures and weak regulatory inspections as a violation of Good Manufacturing Practice (GMP).

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

12902_2023_1459_Article_IEq2.gif

13690_2023_1170_Article_IEq77.gif

12888_2023_5142_Article_IEq13.gif